News and analysis on disease research and diagnostics.
The team anticipates launching its first clinical diagnostic assay, which will detect targeted, low-frequency genetic mutations in lung cancer, in 2021.
Ongoing Scripps research into polygenic risk for coronary artery disease now offers remote genetic counseling as well as an Android app.
Illumina said the NextSeq 2000 and NextSeq 1000 reduce run costs by up to 50 percent, compared to the NextSeq 550 model, while increasing the data output.
Exact Sciences CEO Kevin Conroy discussed the firm's pipeline and plans for 2020 and beyond, while NanoString CEO Brad Gray talked about the company's GeoMx digital spatial profiling technology, among other presentations Wednesday.
Three new studies have found that the presence of B cells in tertiary lymphoid structures in tumors is associated with a favorable response to immunotherapy.
